Latest Articles
AI-based histopathology image analysis reveals a distinct subset of endometrial cancers - Nature.com
AI-based histopathology image analysis reveals a distinct subset of endometrial cancers Nature.com
Published: June 26, 2024, 7 a.m.
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI - Medical Xpress
Scientists discover high-risk form of endometrial cancer—and how to test for it—using AI Medical Xpress
Published: June 26, 2024, 7 a.m.
Episode 2: Quality of Life and Endometrial Cancer Survivorship - Medscape
Episode 2: Quality of Life and Endometrial Cancer Survivorship Medscape
Published: June 25, 2024, 7 a.m.
Endometrial cancer | Healthwatch 16 - WNEP Scranton/Wilkes-Barre
Endometrial cancer | Healthwatch 16 WNEP Scranton/Wilkes-Barre
Published: June 25, 2024, 7 a.m.
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer - OncLive
Frontline Durvalumab/Chemo, Then Maintenance Durvalumab ± Olaparib, Improves ORR in Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology - Cancer Therapy Advisor
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology Cancer Therapy Advisor
Published: June 20, 2024, 7 a.m.
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
Link copied to clipboard!